What is the recommended inpatient management of acute kidney injury (AKI) and the appropriate intravenous fluid rate?

Inpatient Management of AKI and IV Fluid Rate

Use isotonic crystalloids (not colloids) for initial volume expansion in AKI patients, with fluid administration guided by hemodynamic monitoring to achieve adequate perfusion while strictly avoiding fluid overload. 1

Fluid Type Selection

Isotonic crystalloids are the first-line choice for volume expansion in AKI patients (Level 1B recommendation). 1 Specifically:

• Use isotonic crystalloids (0.9% saline or balanced solutions) rather than colloids (albumin or starches) in the absence of hemorrhagic shock
• Avoid starch-containing fluids entirely - they are associated with harm and increased AKI incidence 1
• Balanced crystalloid solutions may be preferable to normal saline to reduce hyperchloremic acidosis risk, though optimal fluid rates and administration methods remain under investigation 2

Special Populations Requiring Albumin:

• Cirrhosis with spontaneous bacterial peritonitis: 1 g/kg/day up to 100 g/day 1, 3
• Large-volume paracentesis in liver disease 1
• Hepatorenal syndrome diagnosis (after 2 days of albumin trial) 3

Fluid Administration Strategy

Initial Resuscitation Phase:

The optimal method of fluid administration (bolus vs. continuous; rate, volume, frequency) remains under active investigation 2, but current evidence supports:

• Early aggressive fluid resuscitation in the initial setting for hemodynamically unstable patients 4
• Protocol-based hemodynamic management targeting adequate perfusion parameters in perioperative and septic shock settings (Level 2C) 1
• Vasopressors in conjunction with fluids for vasomotor shock (Level 1C recommendation) 1
• Target MAP of 65-70 mmHg with norepinephrine unless chronic hypertension present 5

Critical Monitoring Points:

Use dynamic preload indices rather than static pressure measurements to guide fluid responsiveness 6:

• Stroke volume variation
• Pulse pressure variation
• End-expiratory occlusion test
• Passive leg-raising test

These are more reliable than CVP or pulmonary artery occlusion pressure for assessing volume status 6

Avoiding Fluid Overload

Once hemodynamic stability is achieved, transition immediately to fluid restriction - fluid overload is associated with increased mortality and reduced kidney recovery 6, 4. The 2020 KDIGO conference identified detecting and managing fluid overload as a critical research priority 2.

Management Algorithm:

1. Stage 1 AKI (sCr increase 1.5-1.9x baseline):

   • Review and withdraw diuretics if hypovolemia suspected 3
   • Withdraw nephrotoxic drugs (NSAIDs, ACE-I/ARBs, aminoglycosides) 1, 3
   • Provide volume expansion only if clinically hypovolemic 3
   • Monitor sCr every 2-4 days 3

2. Stage 2-3 AKI or fluid-unresponsive patients:

   • Fluid restriction is the treatment of choice 6
   • Do NOT use diuretics to prevent or treat AKI (Level 1B recommendation) - use only for volume overload management (Level 2C) 1
   • Consider renal replacement therapy for refractory fluid overload 1

What NOT to Do

Strong recommendations against specific interventions (Level 1A-1B evidence):

• Do not use low-dose dopamine for AKI prevention or treatment 1
• Do not use diuretics to prevent AKI 1
• Do not use fenoldopam, ANP, or rhIGF-1 1
• Avoid aminoglycosides unless no suitable alternatives exist 1

Nutritional Support

While managing fluids, provide:

• 20-30 kcal/kg/day total energy (Level 2C) 1
• Protein: 0.8-1.0 g/kg/day without dialysis; 1.0-1.5 g/kg/day on RRT; up to 1.7 g/kg/day on CRRT 1
• Enteral route preferred over parenteral 1

Common Pitfalls

1. Continuing aggressive fluid administration after hemodynamic stability - this causes harmful fluid overload 6, 4
2. Using CVP to guide fluid therapy - dynamic indices are superior 6
3. Using diuretics to "protect" kidneys - no benefit, use only for volume overload 1
4. Failing to withdraw nephrotoxic medications early - ACE-I/ARBs, NSAIDs, aminoglycosides must be stopped promptly 1, 3